Epigral Limited's Board of Directors has approved a ₹600 crore capital expenditure to establish a new manufacturing facility at its existing site in Dahej, Gujarat. The strategic investment covers two new projects — an Epoxy Resin & Formulations unit with 1,25,000 tonnes per annum (TPA) capacity and a Multi-Purpose Plant (MPP) — both targeted for completion by the second half of FY2028. The company has outlined an ambitious revenue roadmap, targeting INR 500 crore in revenue by FY29 or FY30, with estimated peak revenue potential of INR 1,300 crore to INR 1,500 crore from these projects.

Project Details and Financing

The expansion involves setting up both an Epoxy Resin & Formulations unit and a Multi-Purpose Plant (MPP), with operations for both targeted to commence by H2FY2028. The total capex for FY27 and FY28 is estimated at INR 400 crore annually, financed through a mix of 60% debt and 40% internal accruals. This structured financing approach is designed to preserve liquidity while leveraging the company's balance sheet strength to support growth.

Revenue Outlook

The board's approval reflects a clearly defined revenue trajectory for the two new projects. The Multi-Purpose Plant is set to be completed by FY28, with the company aiming for INR 500 crore in revenue by FY29 or FY30. Over the longer term, the combined output from the Epoxy Resin & Formulations unit and the MPP is expected to generate peak revenues in the range of INR 1,300 crore to INR 1,500 crore, underscoring the scale of the strategic investment.

Strategic Rationale

The decision underscores Epigral's strategy to diversify its product offerings beyond existing lines. By integrating a multi-purpose plant alongside the dedicated epoxy resin facility, the company aims to serve a broader range of end-use applications. The location in Dahej, an established chemical hub, provides logistical advantages for raw material sourcing and distribution.

Regulatory Disclosure

The approval was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Gaurang Trivedi, Company Secretary & Compliance Officer, signed the disclosure submitted to the National Stock Exchange of India Limited and BSE Limited on July 27, 2026.

Epigral Limited has released the audio recording of its conference call discussing the financial results for the first quarter of FY27. The recording is now accessible to investors and analysts via the company’s official website, providing a detailed review of the quarterly performance that was previously discussed during the live session on July 27, 2026. This disclosure ensures transparency and allows stakeholders who could not attend the live event to access management’s commentary on the company’s operational and financial standing.

The release of the audio file is in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule-III Part-A thereof. The original conference call was held on Monday, July 27, 2026, at 5:00 PM IST, where senior management addressed key performance indicators and strategic updates for Q1 FY27.

Conference Call Overview

The session was led by Epigral Limited’s senior leadership team, offering insights into the quarter’s outcomes. Key participants included Maulik Patel, Chairman and Managing Director; Kaushal Soparkar, Executive Director; Rakesh Agrawal, Chief Financial Officer; and Milind Kotecha, Investor Relations and Strategy. The event was coordinated by Emkay Global Financial Services Ltd., which facilitated the bridge line for domestic and international participants.

Accessing the Recording

Investors can now listen to the complete discussion through the direct link provided by the company. The audio file is hosted on Epigral Limited’s website under the results section, ensuring easy retrieval for record-keeping and analysis purposes.

The communication was signed off by Gaurang Trivedi, Company Secretary & Compliance Officer of Epigral Limited, confirming the authenticity and regulatory compliance of the disclosure. Investors are advised to refer to the official filings for detailed numerical data corresponding to the verbal commentary provided in the recording.